When Genmab announced its $8 billion acquisition of Merus, industry analysts didn’t just see another consolidation … M&A Activity Boosting Biotech Sales Pipelines: How High-Stakes Deals Are Reshaping Pharma InnovationRead more
M&A
When Genmab announced its $8 billion acquisition of Merus, industry analysts didn’t just see another consolidation … M&A Activity Boosting Biotech Sales Pipelines: How High-Stakes Deals Are Reshaping Pharma InnovationRead more